![Thomas Dicker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mr. Thomas Dicker is Managing Partner and is responsible for the creation and marketing of new financial products.
He has over 25 years experience in creating and marketing investment products across Europe.
Mr. Dicker began his career in institutional equity sales at Kidder Peabody in Paris, and moved to Morgan Stanley 6 years later, where he became head of the French institutional equity sales group.
He then joined the Private Client Services group at Morgan Stanley, focusing on High Net Worth individuals and small and medium-sized institutions.
In 1997, Mr. Dicker created, and became Managing Director of the European Private Client Services department of Donaldson, Lufkin, Jenrette (DLJ) in London.
He subsequently became a member of DLJ's International Executive Committee, before leaving in 2002, two years after the acquisition of DLJ by CSFB. Mr. Dicker is a private investor in a number of early stage technology and life science companies.
He graduated from the University of Geneva with a degree in Economic and Social Sciences.
Anciens postes connus de Thomas Dicker
| Sociétés | Poste | Fin |
|---|---|---|
PC Associés SAS
 PC Associés SAS Investment ManagersFinance IPSA is an active manager focused on science-based companies within the European Union. They invest internationally in the ICT, life sciences, natural resources and energy sectors, particularly in France, the UK, Germany, the Netherlands and Denmark. They target high-growth businesses with innovative technology and an experienced management team with a proven track record of growth. They seek board representation, actively participate in strategic decisions, and aim to build their portfolio companies into market leaders. The firm prefers to be the lead or co-lead investor and invests between EUR 1-5 million per round, participating in successive financing rounds. They invest across development stages from startups to pre-IPO companies, and accompany their portfolio companies throughout their development. They favor companies with disruptive products or technology which have reached an advanced stage of development, are likely to generate significant revenues within two to three years, and have exit visibility through IPO or trade sale. In the life sciences sector, IPSA focuses on clinical-stage drug development, medical devices, drug delivery and development services. Their ICT investments are in domains including content, software, enabling technology and infrastructure. The firm also invests in the energy and natural resources sector, focusing on exploration and production, as well as on renewable energy and clean technology. | President | 01/11/2012 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
1
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
PC Associés SAS
PC Associés SAS Investment ManagersFinance IPSA is an active manager focused on science-based companies within the European Union. They invest internationally in the ICT, life sciences, natural resources and energy sectors, particularly in France, the UK, Germany, the Netherlands and Denmark. They target high-growth businesses with innovative technology and an experienced management team with a proven track record of growth. They seek board representation, actively participate in strategic decisions, and aim to build their portfolio companies into market leaders. The firm prefers to be the lead or co-lead investor and invests between EUR 1-5 million per round, participating in successive financing rounds. They invest across development stages from startups to pre-IPO companies, and accompany their portfolio companies throughout their development. They favor companies with disruptive products or technology which have reached an advanced stage of development, are likely to generate significant revenues within two to three years, and have exit visibility through IPO or trade sale. In the life sciences sector, IPSA focuses on clinical-stage drug development, medical devices, drug delivery and development services. Their ICT investments are in domains including content, software, enabling technology and infrastructure. The firm also invests in the energy and natural resources sector, focusing on exploration and production, as well as on renewable energy and clean technology. | Finance |
